Revelation Biosciences (REVB)
(Delayed Data from NSDQ)
$1.94 USD
+0.02 (1.04%)
Updated Jun 4, 2024 03:59 PM ET
After-Market: $1.94 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Revelation Biosciences, Inc. [REVB]
Reports for Purchase
Showing records 21 - 39 ( 39 total )
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
3Q22: Preclinical & Clinical Data Coming In 2023 & 2024, Cash To Mid-2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Positive REVTx-300 Data In Rat Models of AKI & CKD Show Reduced Fibrosis
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Licenses Global Rights to PHAD for Infection from Vanderbilt University
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
2Q22: Preclinical REVTx-200 & REVTx-300 Data in 4Q22, Funded Thru Mid-2023
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
1Q22: REVTx-99b, REVTx-200, & REVDx-501 Moving Forward, Cash Through 2022
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
REVTx-99b Is Believably Less Risky Than REVTX-99a - Data in 2H22
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
REVTx-99a Fails Phase 2b, REVDx-501 Still Encouraging, PT to $9 from $12
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Early 2Q22 Phase 2b Influenza Challenge Results to Be Highly Informative
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Covered Company Developments from Earlier the Week
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Reasons to Sit Down with These Biotech Managements at the 2022 Conference
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Company: Revelation Biosciences, Inc.
Industry: Unclassified
Novel Ways of Thwarting and Diagnosing Respiratory Viral Infection
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J